BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Căpraru OM, Gaillard C, Vasiljevic A, Lasolle H, Borson-Chazot F, Raverot V, Jouanneau E, Trouillas J, Raverot G. Diagnosis, pathology, and management of TSH-secreting pituitary tumors. A single-center retrospective study of 20 patients from 1981 to 2014. Ann Endocrinol (Paris) 2019;80:216-24. [PMID: 31400861 DOI: 10.1016/j.ando.2019.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel) 2020;12:E514. [PMID: 32098443 DOI: 10.3390/cancers12020514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
2 Guadagno E, D'Avella E, Cappabianca P, Colao A, Del Basso De Caro M. Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature. J Endocrinol Invest 2020;43:1429-45. [PMID: 32415572 DOI: 10.1007/s40618-020-01275-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Silva-Ortega S, García-Martinez A, Niveiro de Jaime M, Torregrosa ME, Abarca J, Monjas I, Picó Alfonso A, Aranda López I. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors. Hum Pathol 2021;110:20-30. [PMID: 33321163 DOI: 10.1016/j.humpath.2020.12.001] [Reference Citation Analysis]
4 Gatto F, Arvigo M, Ferone D. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Invest 2020;43:1543-53. [PMID: 32557353 DOI: 10.1007/s40618-020-01335-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]